3Van Oosterom AT, Judson J, Verweij E, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours:a phase I study[J]. The Lancet, 2001,358(27):1421-1423.
4Mazur MT, Clark HB. Gatric stromal tumors: reappraisal of histogenesis[J]. Am J Surg Pathol, 1983,7(16) : 507-519.
5Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhabitor STI571 in a patient with a matastatic gastrointestinal stromal tumor[J]. N Eng J Med, 2001,344(14): 1052-1056.
7Blanks CD, von Mehren M, Tuveson S, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy,STI571, in patient with unresectable or metastatic expressing c-kit(CD117)[J]. Proc Am Soc Clin Oncol, 2001,20(pt 1):1 a. abstracts1.
8Demetri GD, von Mehren M, Blande CD, et al. efficacy and safety of imatinib mesylate mesylate in advanced gastrointestinal stromal tumors[J]. N Eng J Med, 2002,347(7): 472-480.
9Ryu M H, Kim T W, Chang H M, et al. Efficacy of imatinib mesylate in metastatic or unresectable malignant gastrointestinal stromal tumor(GIST)[M]. ASCO Proc,2003.3312a.
10Bumming P, Andersson J, Meis-Kindblom JM, et, al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib mesylate: a centrebased study of 17 patients[J]. British Journal of Cancer,2003,89 (8) :460-464.
